Epidemiology and disease characteristics of systemic sclerosis-related pulmonary arterial hypertension: results from a real-life screening programme

Kathleen Morrisroe1,2, Wendy Stevens2, Joanne Sahhar3, Candice Rabusa2, Mandana Nikpour1,2*, Susanna Proudman4,5† the Australian Scleroderma Interest Group (ASIG)

Abstract

Background: Pulmonary arterial hypertension (PAH) is the leading cause of death in systemic sclerosis (SSc). Annual screening with echocardiogram (ECHO) is recommended. We present the methodological aspects of a PAH screening programme in a large Australian SSc cohort, the epidemiology of SSc-PAH in this cohort, and an evaluation of factors influencing physician adherence to PAH screening guidelines.

Methods: Patient characteristics and results of PAH screening were determined in all patients enrolled in a SSc longitudinal cohort study. Adherence to PAH screening guidelines was assessed by a survey of Australian rheumatologists. Summary statistics, chi-square tests, univariate and multivariable logistic regression were used to determine the associations of risk factors with PAH.

Results: Among 1636 patients with SSc, 194 (11.9%) had PAH proven by right-heart catheter. Of these, 160 were detected by screening. The annual incidence of PAH was 1.4%. Patients with PAH diagnosed on subsequent screens, compared with patients in whom PAH was diagnosed on first screen, were more likely to have diffuse SSc (p = 0.03), be in a better World Health Organisation (WHO) Functional Class at PAH diagnosis (p = 0.01) and have less advanced PAH evidenced by higher mean six-minute walk distance (p = 0.03), lower mean pulmonary arterial pressure (p = 0.009), lower mean pulmonary vascular resistance (p = 0.006) and fewer non-trivial pericardial effusions (p = 0.03). Adherence to annual PAH screening using an ECHO-based algorithm was poor among Australian rheumatologists, with less than half screening their patients with SSc of more than ten years disease duration.

Conclusion: PAH is a common complication of SSc. Physician adherence to PAH screening recommendations remains poor. Identifying modifiable barriers to screening may improve adherence and ultimately patient outcomes.

Keywords: Systemic sclerosis, Scleroderma, Pulmonary arterial hypertension, Screening algorithm

* Correspondence: m.nikpour@unimelb.edu.au
† Equal contributors
1Department of Medicine, The University of Melbourne at St Vincent’s Hospital (Melbourne), 41 Victoria Parade, Fitzroy 3065, Victoria, Australia
2Departments of Rheumatology and Medicine, The University of Melbourne at St Vincent’s Hospital (Melbourne), 41 Victoria Parade, Fitzroy 3065, Victoria, Australia
Full list of author information is available at the end of the article

© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Systemic sclerosis (SSc) is a multisystem connective tissue disease (CTD) characterised by vasculopathy and fibrosis [1]. There is no cure for SSc, leading to significant morbidity, mortality and poor health-related quality of life [2, 3].

Cardiopulmonary manifestations, namely interstitial lung disease (ILD) and pulmonary arterial hypertension (PAH), have replaced SSc renal crisis (SRC) as the leading cause of mortality in SSc [4, 5].

SSc-PAH occurs with a prevalence of 8–12% [6] and is the second most common cause of PAH after idiopathic PAH [7]. PAH is characterised by abnormal proliferation, vasoconstriction and thrombosis of the pulmonary vasculature, leading to elevated pulmonary vascular resistance (PVR), resulting in right-heart failure and death [8]. Despite new pulmonary vasodilator therapies that improve symptoms and survival [9–16], one-year and three-year survival remains poor (78% and 47%, respectively) [17, 18], less than that of idiopathic and other connective tissue disease (CTD)-associated PAH [18]. Risk factors for the development of SSc PAH include anti-centromere antibody, telangiectasia, calcinosis, oesophageal stricture, sicca symptoms, mild ILD and digital ulcers [19, 20], although none of these perform sufficiently well as indicators in the individual patient and are often inconsistent between studies.

Early recognition of SSc-PAH is difficult as early disease is clinically silent and the heterogeneous nature of SSc makes interpretation of fatigue and dyspnoea challenging [21]. Survival is improved even after adjustment for lead-time bias in SSc-PAH when diagnosed by screening compared with diagnosis during routine care [9–14]. Consequently, annual screening with transthoracic echocardiogram (TTE) and pulmonary function tests (PFTs) is recommended [22], regardless of the presence or absence of the aforementioned risk factors, to identify patients who should undergo right-heart catheterisation (RHC) to confirm the diagnosis.

Despite the documented benefit of PAH screening, physician adherence is suboptimal, with one study showing that only 34.7% of patients with SSc had a TTE and 53.1% had PFT in the twelve months prior to PAH diagnosis [23]. Adherence among Australian physicians is no better, with over 40% not adhering to annual screening and even fewer using RHC for PAH diagnosis [24]. Consequently, the Australian Scleroderma Cohort Study (ASCs), a longitudinal multi-centre study, was established in 2007 as a web-based screening platform for the cardiorespiratory manifestations of SSc.

In this paper, we present the methodological aspects of establishing the ASCS and the screening algorithm, the characteristics of patients with SSc with PAH in this cohort and an evaluation of the factors influencing Australian rheumatologists’ adherence to screening guidelines.

Methods

Study centres
The ASCS is a nationwide project wherein patients with SSc are recruited from 13 participating centres across Australia. SSc experts were invited by a core group of rheumatologists to form the Australian Scleroderma Interest Group (ASIG) and to take part in the ASCS through recruitment of patients and collection of data at their centres. Physicians who are not at an ASIG centre and care for patients with SSc are invited to refer patients for the screening service, while ongoing care between screening visits remains their responsibility.

Patients
All patients with SSc, defined according to American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) criteria [25] or Leroy/Medsger criteria [26], and mixed connective tissue disease (MCTD), as originally described by Sharp et al. [27], are eligible for enrolment. Patients provide written informed consent for collection of de-identified data, chart review, and storage of serum and DNA for future studies. All research ethics committees of the participating sites have approved ASCS.

Data collection and database
Comprehensive demographic and disease-related data are collected annually and entered into a custom-made database hosted by St. Vincent’s Hospital Melbourne using a remote secure access token. A log is kept of all users and the database is backed up daily. Logic checks are used to detect errors in data entry and incomplete entries.

Screening algorithm for early detection of PAH
Participation in the ASCS mandates annual application of a PAH screening algorithm created by a panel of Australian rheumatologists, cardiologists and respiratory physicians (Fig. 1) based on the European Society of Cardiology (ESC)/European Respiratory Society (ERS) guidelines [28, 29]. According to Fig. 1, investigations are recommended for symptomatic patients with low probability of PAH, and irrespective of symptoms for patients with moderate or high probability of PAH [30].

Clinical decision support tool
If any value falls outside a predetermined range for systolic pulmonary arterial pressure (sPAP) on TTE, diffusing capacity of the lung for carbon monoxide (DLCO) corrected for haemoglobin, and/or forced vital capacity (FVC) according to the screening algorithm, an email to the treating physician is automatically generated, indicating why the alert has been triggered and recommending a course of action. If the physician chooses not to follow the algorithm he/she must justify this decision.
Adherence to published recommendations for annual PAH screening
Non-ASIG physicians’ screening practices and adherence to published recommendations for PAH screening [24, 28, 29] were assessed by means of a cross-sectional survey (Additional file 1: Table S1 using survey monkey circulated through the Australian Rheumatology Association following the establishment of ASCS in 2007. The survey addressed existing screening practices based on SSc disease subtype and disease duration (early or late defined as <10 or ≥10 years from the first non-Raynaud’s disease manifestation, respectively), barriers to screening encountered by physicians and suggestions for streamlining screening.

Statistics
For the purpose of statistical analysis, de-identified aggregated data are exported in .txt and .xml format. Characteristics of patients in the study are presented as mean (standard deviation (SD)) or number (percentage). We compared dichotomous variables using the chi-square test. Continuous variables were compared using the t test for normally distributed data and the Wilcoxon rank-sum (Mann-Whitney) test for non-parametric data. All-cause mortality was used for survival analyses. Kaplan-Meier (K-M) curves were used to estimate survival in patients with SSc-PAH diagnosed at first screen versus subsequent screen. The date of PAH diagnosis on RHC was considered the baseline from which survival was calculated. Log-rank and Wilcoxon tests were used to compare survival curves.

Results
Recruitment
A total of 1636 patients were recruited into ASCS from July 2007 to July 2016 (census date). Recruitment comprised new referrals from general practitioners for comprehensive specialist management, and from rheumatologists requesting the PAH screening service only. The number of patients recruited, relative to the predicted prevalence of SSc in Australia [31, 32] and...
population data from the Australian Bureau of Statistics [33] were estimated.

**Patient characteristics and follow up**

Of the 1636 patients, 1243 (75.9%) had been seen within the 18 months before the census date and were considered “current” (Table 1). The period of 18 months was selected to allow for delays in data entry. Patient characteristics and follow-up status are summarised in Table 1.

Patients with limited disease (lcSSc) were older at recruitment than patients with diffuse disease (dcSSc) (58.8 ± 12.2 vs 53.1 ± 13.1 years, p < 0.001) with longer disease duration from first non-Raynaud’s clinical manifestation (12.2 ± 10.8 vs 8.1 ± 8.7 years, p < 0.001). ILD was more prevalent in the patients with dcSSc (40.9% vs 21.1%) but there was no significant difference in the prevalence of PAH (10.1% vs 12.7%, p = 0.40) (Table 2).

In total, 232 patients (14.2%) were diagnosed with pulmonary hypertension (PH). Of these, 194 patients (83.6%) had World Health Organisation (WHO) Group I PAH according to the criteria developed in Nice [34], 15 patients (6.5%) had exercise-induced PH, 18 patients (7.8%) had PH secondary to left ventricular dysfunction (WHO Group 2 PH) and 5 patients (2.2%) had PH secondary to ILD (WHO Group 3 PH). Only patients with WHO Group I PAH were analysed in this study.

At enrollment, 34 (2.1%) patients had previously been diagnosed with PAH and 122 (7.5%) were diagnosed at their first contact with ASCS. Among the latter, 89 (72.9%) had SSc disease duration of ≥ 4 years and the date of their last TTE was 1.6 ± 4.6 years before enrollment to ASCS, highlighting a lack of adherence to annual PAH screening in the community.

**Outcomes of screening in the ASCS**

A total of 4326 screening visits were analysed, to determine the success of, and adherence to the PAH screening algorithm (Table 3). Only patients not previously diagnosed with PAH were included. At the first screening visit, sufficient data to apply the screening algorithm were available for 1363 patients. Of these, 101 patients (7.4%) were at high risk of PAH, 121 patients (8.9%) at moderate risk, 358 patients (26.3%) at low risk and 470 patients (34.5%) at no increased risk based on TTE and PFT results. The number of patients with no tricuspid regurgitation (TR) on TTE, and hence inestimable sPAP, was high at 313 (22.9%).

At the first screening visit, 157 of the 580 (27.1%) patients at low risk (38/358), moderate (36/121), or high (83/101) risk of PAH underwent RHC. WHO Group 1 PAH was diagnosed in 122 patients (8.9% of the cohort), including 4 of 19 (21.0%) patients with a normal TTE and 10 of 24 patients (41.7%) with a missing sPAP on TTE due to lack of a TR jet. The patients in the latter two groups were referred for RHC due to reduced exercise capacity and/reduced DLCO. Only 4% of the patients with no TR were referred for RHC but 36.8% of these

---

**Table 1** Characteristics of patients recruited up to July 2016 (n = 1636)

| Characteristic | Number (%) or mean ± SD |
|---------------|-------------------------|
| Patient number | 1636                    |
| Gender (female:male) | 6.4:1 (86.1% vs 13.9%) |
| Race          |                         |
| Caucasian     | 1390 (91.9%)            |
| Asian         | 75 (4.9%)               |
| Aboriginal-Islander | 18 (1.2%)           |
| Hispanic      | 11 (0.7%)               |
| Other         | 19 (1.3%)               |
| Age at recruitment, mean ± SD, years | 57.2 ± 12.8               |
| Disease duration at recruitment*, years | 10.9 ± 10.2               |
| Recruited within 4 years of first non-Raynaud’s feature | 435                    |
| Age at diagnosis of PAH if present, years | 62.9 ± 11.1               |
| Number of study visits |                      |
| One           | 364 (22.3%)             |
| Two           | 325 (19.9%)             |
| Three         | 216 (13.2%)             |
| Four          | 199 (12.2%)             |
| Five          | 165 (10.1%)             |
| Six           | 119 (7.3%)              |
| Seven         | 71 (4.3%)               |
| Eight         | 79 (4.8%)               |
| Nine          | 845 (5.2%)              |
| Ten           | 14 (0.9%)               |
| Duration of follow up, mean ± SD, years | 3.7 ± 2.7               |
| Patient status |                         |
| Current       | 1243 (76.5%)            |
| Withdrawn     | 101 (6.2%)              |
| Dead          | 220 (13.5%)             |
| Lost to follow up | 61 (3.8%)           |
| Disease subtype |                         |
| Limited       | 1122 (68.6%)            |
| Diffuse       | 377 (23.0%)             |
| MCTD          | 83 (5.3%)               |
| Autoantibody profile |                   |
| ANA positive (n = 1508) | 1418 (94.0%)          |
| Anti-centromere (n = 1497) | 673 (44.9%)          |
| Anti-Scl70 (n = 1483) | 205 (13.8%)            |
| Anti-RNAP (n = 794) | 125 (13.1%)            |

*Disease duration from first non-Raynaud manifestation. Numbers of variables analysed (n =) are included in each section of the table to acknowledge any missing data. Patient status: current patients were defined as being seen in the last 2 years, withdrawn patients have withdrawn their consent from participating in the database and lost to follow up is defined as patients who, despite multiple attempts, we have been unable to contact for >18 months. PAH pulmonary arterial hypertension, MCTD mixed connective tissue disease, ANA antinuclear antibody, Anti-RNAP anti-RNA polymerase
were diagnosed with WHO Group 1 PAH. At the
physician’s discretion and based on other indicators
such as patient symptoms and TTE parameters,
patients whose initial RHC was negative for PAH
were considered for future RHC.

The screening algorithm correctly identified patients
at increased risk of PAH and stratified them by level of
risk. The higher the probability of PAH, the more likely
PAH was to be identified on RHC (Table 3). A new
diagnosis of WHO Group I PAH was made in 160
patients from 4326 (3.7%) screening visits (115/1122
with lcSSc, 32/377 with dcSSc and 10/83 with MCTD),
giving a prevalence of PAH of 11.8% (10.3% in lcSSc,
8.5% in dcSSc and 12.0% in MCTD). The annual preva-
ance of PAH was 1.4% (1.2% in lcSSc, 0.9% in dcSSc,
0.4% in MCTD). All patients were treated with specific
PAH therapy.

### Characteristics of patients with PAH

Patients with PAH were significantly older than patients
without PAH (63.1 vs 56.3 years, \( p < 0.001 \)), had longer
disease duration (13.6 vs 10.4 years, \( p < 0.001 \)) and were
in WHO Functional Class III/IV (85.0% vs 21.7%, \( p < 0.001 \))
(Table 4). Clinical manifestations and autoantibody status
are summarised in Table 4.

### Characteristics of patients with PAH diagnosed on first
screen compared with patients whose PAH was
diagnosed on subsequent screens

To assess whether the ASCS screening programme
succeeded in detecting PAH at an earlier stage, we divided
our PAH cohort into those patients whose PAH was
detected on first screening and those whose PAH was
detected on the second or subsequent screen (Table 5).

We believe that PAH detected on first screen were
likely to be a “delayed diagnosis” in patients who were
referred to ASCS due to symptoms or clinical suspicion
of PAH, whereas PAH detected on subsequent screens
was more likely to be an “incident” PAH identified on
earlier screening.

Patients diagnosed with PAH on subsequent screens
compared with first screen were more likely to have
dcSSc (35.1% vs 15.9%, \( p = 0.03 \)), be in a better WHO
functional class (54.1% vs 75.9% in Class III, 5.4% vs
16.2% in Class IV, \( p = 0.01 \)) and have less advanced
PAH at diagnosis evidenced by lower mPVR (3.8 vs
5.5, \( p = 0.005 \)), higher mean 6MWD (340.6 vs 295.9,
\( p = 0.05 \)), lower mPAP (32.5 vs 38.2, \( p = 0.03 \)), and fewer
non-trivial pericardial effusions (2.7% vs 16.0%, \( p = 0.03 \)).

PAH treatment with combination therapy and anticoa-
gulation therapy was prescribed at a similar rate in those
diagnosed at subsequent screens (36.8% and 28.9%,
respectively) and those diagnosed at first screen (32.1%
and 26.8%, respectively). Three-year survival from the
time of PAH diagnosis was better in those diagnosed on
subsequent screen compared with those diagnosed at first
screen as outlined in Fig. 2 (94.7% vs 42.7%, \( p < 0.001 \)) and
mean time to death was longer in those diagnosed with
PAH on subsequent screens compared with those diag-
nosed at first screen (4.7 ± 2.3 vs 2.3 ± 2.3, \( p < 0.001 \)). PAH
was the direct cause of death in 100% of patients
diagnosed on subsequent screen and in 92.7% of those
diagnosed on first screen (\( p = 0.40 \)).

### Adherence to the ASCS screening algorithm

ASIG physicians’ adherence to PAH screening guidelines
was high with 84.4% of patients undergoing annual
screening over a ten-year period. Despite the screening
algorithm (Fig. 1) mandating that patients at moderate
or high risk of PAH should undergo RHC, only 29.7%
(170/572) had RHC. Even among those in the high prob-
ability group, only 59.1% of patients underwent RHC.
Physician justification for not performing RHC predomi-
nantly related to their WHO functional class. In 50.5%
of cases, RHC was not performed as the patient was in
WHO Functional Class I (31.6%), or Class II (14.7%) or
was not dyspnoeic (4.2%). In 18.9% of cases, the
physician referred the patient to another specialist for
their opinion, most commonly a cardiologist or respiratory
physician. In 16.8% of cases, the physician was deterred

### Table 2 Characteristics of patients with SSc by disease subset

|               | Limited | Diffuse | \( P \) value |
|---------------|---------|---------|-------------|
| n             | 1122    | 377     |             |
| mean ± SD or %| 58.8 ± 12.2 | 53.1 ± 13.1 | <0.001 |
| Disease duration\( ^a \) (non-Raynaud) | 12.2 ± 10.8 | 8.1 ± 8.7 | <0.001 |
| Anti-centromere pattern ANA | 59.2% | 9.6% | <0.001 |
| RNA polymerase III positive | 5.4% | 39.6% | <0.001 |
| ILD (HRCT scan) | 236 (21.1%) | 154 (40.9%) | <0.001 |
| PAH (RHC) | 142 (12.7%) | 38 (10.1%) | 0.40 |
| Rodnan skin score (highest ever) | 7.7 ± 5.4 | 22.7 ± 9.9 | <0.001 |
| Digital ulcers ever | 39.6% | 60.8% | <0.001 |
| Joint contractures ever | 28.5% | 71.2% | <0.001 |
| Renal crisis ever | 0.9% | 7.7% | <0.001 |
| Gastro-oesophageal reflux | 80.3% | 82.7% | 0.29 |
| Anal incontinence | 27.9% | 25.6% | 0.39 |

\( ^a \)Disease duration defined as from first non-Raynaud's disease manifestation.

*ANA antinuclear antibodies, ILD interstitial lung disease, HRCT high-resolution chest computed tomography, PAH pulmonary arterial hypertension, RHC right-heart catheterisation.
Table 3: Diagnosis of WHO Group I PAH by risk stratification using the screening algorithm

| Review number | Screened, n | No increased probability | Low probability of PAHa | Moderate probability of PAHb | High probability of PAHc | Missing sPAP | Total with PAH, n |
|---------------|-------------|--------------------------|-------------------------|-----------------------------|-------------------------|--------------|------------------|
|               |             | Normal TTE, n | RHC, n | PAH, n | Moderate TTE, n | RHC, n | PAH, n | TTE, n | RHC, n | PAH, n | No. with PAH, n | RHC, n | PAH, n | Positive screen, n |
| 1st screen    | 1363        | 470          | 19     | 4      | 358           | 38     | 11     | 121    | 36    | 25    | 101          | 83    | 72    | 313             | 24    | 10    | 122              | (8.9%) |
| 2nd screen    | 896         | 355          | 6      | 2      | 229           | 5      | 3      | 78     | 10    | 4     | 32           | 11    | 5     | 202             | 8     | 3     | 17               | (1.9%) |
| 3rd screen    | 679         | 272          | 0      | 0      | 167           | 4      | 1      | 65     | 5     | 3     | 20           | 7     | 6     | 155             | 3     | 1     | 11               | (1.6%) |
| 4th screen    | 482         | 199          | 0      | 0      | 125           | 3      | 0      | 42     | 7     | 2     | 13           | 5     | 3     | 103             | 1     | 0     | 5                | (1.0%) |
| 5th screen    | 361         | 149          | 0      | 0      | 104           | 0      | 0      | 25     | 1     | 1     | 9            | 4     | 1     | 74              | 1     | 0     | 2                | (0.6%) |
| 6th screen    | 235         | 91           | 0      | 0      | 72            | 1      | 1      | 25     | 1     | 1     | 6            | 0     | 0     | 41              | 0     | 0     | 2                | (0.9%) |
| 7th screen    | 162         | 66           | 0      | 0      | 48            | 0      | 0      | 14     | 0     | 0     | 3            | 0     | 0     | 31              | 1     | 0     | 0                | (0.0%) |
| 8th screen    | 104         | 48           | 0      | 0      | 27            | 1      | 1      | 10     | 0     | 0     | 1            | 0     | 0     | 18              | 0     | 0     | 0                | (0.0%) |
| 9th screen    | 43          | 20           | 0      | 0      | 11            | 1      | 1      | 6      | 0     | 0     | 1            | 0     | 0     | 5               | 0     | 0     | 1                | (2.3%) |
| 10th screen   | 1           | 0            | 0      | 0      | 0             | 1      | 0      | 0      | 0     | 0     | 0            | 0     | 0     | 0               | 0     | 0     | 0                | (0.0%) |
| Total         | 4326        | 1670         | 25b    | 6b    | 1142          | 53b    | 17b   | 386    | 60b   | 36a   | 186          | 110b  | 87a  | 942             | 38b   | 14a  | 160             | (1.7%) |

aProbability of pulmonary arterial hypertension (PAH): no increased probability of PAH was indicated by systolic pulmonary arterial pressure (sPAP) <30 and diffusing capacity of the lung for carbon monoxide corrected for haemoglobin (DLCO) >50%, low probability of PAH was indicated by 30 ≤ sPAP <40 mmHg with normal forced vital capacity (FVC) and high-resolution computed tomography (HRCT), moderate probability of PAH was 40 ≤ sPAP <50 mmHg OR DLCO <50% and FVC <85% or annual fall in DLCO ≥20% or unexplained dyspnea and high probability of PAH was indicated by sPAP ≥50 mmHg.

bPercentage of patients who were detected by transthoracic echocardiogram (TTE) to be in a risk category and underwent right-heart catheterisation (RHC).

cPercentage of patients who underwent RHC and were diagnosed with World Health Organisation (WHO) Group I PAH.
from arranging RHC due to the presence of mild ILD that they felt accounted for the TTE or PFT result. The remaining justifications included a plan to repeat the TTE and/or PFT at a later date (4.2%), patient refusal to have RHC (2.1%), terminal malignancy (2.1%) and no access to RHC (1.1%).

Adherence to PAH screening guidelines by Australian rheumatologists after the establishment of the ASCS screening programme in 2007

Of 334 non-ASIG Australian rheumatologists, 52 responded to the survey on screening practices and barriers to screening (Additional file 1: Table S1). The majority (88.9%) reported screening asymptomatic patients for PAH regularly. Just over half of the respondents ordered annual screening for their asymptomatic patients with early SSc (lcSSc 58.9%, dcSSc 52.6%), with even fewer screening annually in late disease (lcSSc 38.5%, dcSSc 43.6%). All respondents (100%) would investigate their patients with symptoms consistent with PAH. In early symptomatic SSc (with breathlessness or reduced exercise tolerance), the majority of respondents would screen on a six-monthly (51.2%) or annual basis (33.6%). In late symptomatic SSc, 38.9% of respondents would screen their patients six-monthly and 41.2% of respondents would screen annually. Alarmingly, 17.5% of respondents would only screen symptomatic patients every two years.

### Table 4 Characteristics of patients with SSc by PAH status

| Characteristic                  | PAH detected on first screening mean ± SD or % | No PAH detected on first screening mean ± SD or % | P value |
|--------------------------------|---------------------------------------------|-----------------------------------------------|---------|
| Number of patients             | 209                                         | 1283                                         |         |
| Age at recruitment, years     | 63.1 ± 10.4                                 | 56.3 ± 12.7                                 | <0.001 |
| Disease duration at recruitment, years* | 13.6 ± 11.5                           | 10.4 ± 9.9                                 | <0.001 |
| Female                         | 87.1%                                       | 86.2%                                       | 0.88    |
| Limited disease subtype        | 73.9%                                       | 70.3%                                       | 0.43    |
| Anti-centromere pattern ANA    | 52.6%                                       | 44.1%                                       | 0.02    |
| Scl 70 positive                | 6.9%                                        | 15.2%                                       | 0.003   |
| RNA polymerase III positive    | 14.4%                                       | 12.9%                                       | 0.65    |
| Digital ulcers ever            | 53.0%                                       | 41.9%                                       | 0.003   |
| Telangiectasia ever            | 91.4%                                       | 82.4%                                       | <0.001  |
| Calcinosis ever                | 53.3%                                       | 34.7%                                       | <0.001  |
| Joint contractures ever        | 45.8%                                       | 35.7%                                       | 0.007   |
| GORD                           | 45.9%                                       | 45.3%                                       | 0.46    |
| Bowel dysmotility              | 27.3%                                       | 22.7%                                       | 0.15    |
| Anal incontinence              | 32.1%                                       | 25.7%                                       | 0.05    |
| WHO Functional Class           |                                             |                                             |         |
| Class I                        | 4 (2.1%)                                    | 467 (39.1%)                                 | <0.001  |
| Class II                       | 25 (12.9%)                                  | 469 (39.2%)                                 |         |
| Class III                      | 106 (54.9%)                                 | 238 (19.9%)                                 |         |
| Class IV                       | 58 (30.1%)                                  | 22 (18.8%)                                  |         |
| NT-pro-BNP                     | 218.9 ± 285.7                               | 75.1 ± 159.8                                | 0.005   |

PAH pulmonary arterial hypertension, ANA antinuclear antibodies, 6MWD six minute walk distance, mPAP mean pulmonary arterial pressure, mRAP mean right atrial pressure, PVR pulmonary vascular resistance, GORD gastro-oesophageal reflux disease, WHO World Health Organisation, NT-pro-BNP N-terminal pro b-type natriuretic peptide

*Disease duration defined as from first non-Raynaud’s disease manifestation

Disease manifestations defined as present if ever present from systemic sclerosis (SSc) diagnosis

### Table 5 Comparison of demographic, clinical and haemodynamic characteristics of patients with PAH diagnosed at first screen and PAH diagnosed at subsequent screens

| Characteristic                  | PAH detected on first screening mean ± SD or % | PAH detected on subsequent screening mean ± SD or % | P value |
|--------------------------------|---------------------------------------------|-----------------------------------------------|---------|
| Number of patients             | 122                                         | 38                                           |         |
| Age at PAH diagnosis           | 63.9 ± 11.0                                 | 62.7 ± 9.5                                  | 0.56    |
| Disease duration at PAH diagnosis | 13.4 ± 12.8                           | 14.6 ± 8.7                                  | 0.62    |
| Female                         | 96 (85.7%)                                  | 32 (84.2%)                                  | 0.82    |
| Disease subtype                |                                             |                                              |         |
| Limited                         | 81 (75.7%)                                  | 23 (62.2%)                                  | 0.03    |
| Diffuse                        | 17 (15.9%)                                  | 13 (35.1%)                                  |         |
| MCTD                           | 9 (8.4%)                                    | 1 (2.7%)                                    |         |
| Status                         |                                             |                                              |         |
| Alive                          | 54 (48.2%)                                  | 26 (68.4%)                                  | 0.03    |
| Dead                           | 55 (49.1%)                                  | 10 (26.3%)                                  |         |
| Withdrawn                      | 3 (2.7%)                                    | 1 (2.6%)                                    |         |
| Unable to contact              | 0 (0%)                                      | 1 (2.6%)                                    |         |
| Follow up, years               | 3.3 ± 2.4                                   | 5.9 ± 1.9                                   | <0.001  |
| WHO class at PAH diagnosis     |                                             |                                              |         |
| Class I                        | 4 (4.0%)                                    | 0 (0%)                                       | 0.01    |
| Class II                       | 16 (16.2%)                                  | 15 (40.5%)                                  |         |
| Class III                      | 63 (75.9%)                                  | 20 (54.1%)                                  |         |
| Class IV                       | 16 (16.2%)                                  | 2 (5.4%)                                    |         |
| 6MWD at PAH diagnosis          | 295.9 ± 118.3                               | 340.6 ± 115.6                               | 0.05    |
| mPAP on RHC                    | 38.2 ± 11.4                                 | 32.5 ± 8.3                                  | 0.005   |
| mRAP on RHC                    | 9.7 ± 8.5                                   | 84 ± 3.9                                    | 0.40    |
| PVR on RHC                     | 5.5 ± 3.1                                   | 3.8 ± 1.7                                   | 0.005   |
| CI on RHC                      | 2.9 ± 1.6                                   | 2.9 ± 0.7                                   | 0.87    |
| Pericardial effusion           | 16 (16.0%)                                  | 1 (2.7%)                                    | 0.03    |

Probability of PAH

PAH pulmonary arterial hypertension, MCTD mixed connective tissue disease, WHO World Health Organisation, 6MWD six-minute walk distance, mPAP mean pulmonary arterial pressure, RHC right-heart catheterization, mRAP mean right atrial pressure, PVR pulmonary vascular resistance, CI cardiac index, NT-pro-BNP N-terminal pro b-type natriuretic peptide
Explanations for not following guidelines for PAH screening included cost of screening (60%) and concerns about how to interpret the results (80%). In order to improve screening, 50% of respondents felt that they required better guidelines for the selection and frequency of screening tests. 44.7% wanted a reminder system, 42.1% wanted guideline simplification but only 31.6% felt that access to an experienced screening centre would be helpful. If reimbursed by Medicare Australia, 76.3% of respondents would consider the use of a blood test such as N-terminal pro B-type natriuretic peptide (NT-pro-BNP) a major advance.

**Discussion**

We present the ASCS as a model of multi-centre web-based data collection and decision support for applying a PAH screening algorithm in patients with SSc. Between 2007 and 2016, 1636 patients with SSc were recruited, an estimated 30.9% of all Australian patients with SSc based on a prevalence of 20 per 100,000 people. As Australia has such sparse population density and SSc is a low-frequency disease, such multicentre collaborations are required in order to recruit and retain sufficient patients for a longitudinal observational study.

The patient characteristics of our cohort are comparable to those of other large multi-centre cohorts indicating that a representative sample is being recruited [35]. As a result of screening, 160 patients were diagnosed with PAH over a ten-year period, providing an annual PAH of 1.4%, consistent with that of the French *ItinerAIR-Sclerodermie* Study of 0.6% [36] and a prevalence of 11.8% consistent with worldwide data [13, 36–39].

As in other cohorts [40, 41], patients with PAH were older, had longer disease duration from the first non-Raynaud’s clinical manifestation, were more likely to be anti-centromere (ACA)-positive and to have digital ulcers, telangiectasia, calcinosis and joint contractures compared to those without PAH. Patients with PAH detected on the second or subsequent screen were more likely to have dcSSc, be in a better WHO Functional Class at PAH diagnosis and have less advanced PAH, which is consistent with the French data [36] but different from the classical teaching that PAH more commonly develops in patients with lcSSc [42].

Additionally, patients with PAH diagnosed on subsequent screen compared with first screen had significantly improved survival (p < 0.001) and a longer mean time to death (4.7 ± 2.3 vs 2.3 ± 2.3, p < 0.001), which may in part be due to lead-time bias. Our one-year and three-year survival in patients diagnosed with PAH on subsequent visits are similar to the survival rates in the PHAROS registry [14], one of the few other studies evaluating survival in incident SSc-PAH diagnosed on RHC. These survival rates are higher than those reported in other registries containing a mixture of patients with both incident and prevalent SSc-PAH or PAH diagnosed on TTE rather than RHC [38, 43, 44]. Diagnosis of early PAH is particularly important as patients with early PAH can progress rapidly, supporting the need for early treatment in this patient population [12].

Despite the majority of patients in the ASCS being screened annually, only 29.7% (170/572) of patients deemed at moderate or high risk of PAH were referred for RHC, predominantly due to preservation of functional class limiting patient eligibility for PBS-funded PAH therapy. Concern about the small but documented risk involved in RHC may also have deterred physicians from referring for RHC but this information was not specifically sought. These results highlight external factors that limit adherence to international screening recommendations.

The number of patients with no TR on TTE, and hence inestimable sPAP, was high at 21.8%, but consistent with the 20–30% reported in the literature [45]. Only 4% of these patients were referred for RHC, with 36.8% diagnosed with WHO Group 1 PAH. This highlights the need for a non-TTE dependent method of PAH screening and supports the emerging role of NT-pro-BNP, which is increased in PAH and in those at increased risk [46]. This test is not currently reimbursed for this indication in Australia and thus is not often performed.

Since the establishment of ASCS in 2007, Australian rheumatologists’ adherence to screening guidelines has improved, with 88.9% of physicians regularly screening asymptomatic patients with SSc for PAH compared with 55.8% previously [29]. Of those who did not perform TTE for PAH screening, 50% reported this was due to difficulty assessing the right heart pressures with TTE. Referral of these patients to a tertiary screening centre may overcome this obstacle. To our knowledge, there have been no other studies addressing physicians’ perceived barriers to SSc-PAH screening.
Limitations to our study include the potential for lead-time and length-time bias to impact on the survival benefit seen in PAH detected with screening. However, patients detected by screening were functionally impaired at the time of diagnosis and were all commenced on PAH therapy, indicating that their physician felt that their PAH required treatment. Our data analyses were conducted in patients who underwent all procedures listed in our screening algorithm; therefore, the incidence of PAH in our study may be an underestimate, although consistent with the literature. Additionally, only 15.6% of non-ASIG Australian rheumatologists responded to our survey on PAH screening adherence. Therefore these particular results may not be a true reflection of rheumatologists nationwide.

Conclusion

SSc-PAH is a tragic consequence of SSC, which despite advances in therapy, is the leading cause of SSc-related death. Screening with a web-based algorithm can identify patients with earlier PAH and improve outcomes. Identifying modifiable barriers to screening may improve adherence and ultimately patient outcomes.

Additional file

Additional file 1: Table S1. Cross-sectional survey of physician adherence to PAH screening recommendations. (DOC 97 kb)

Abbreviations

ASCS: Australian Scleroderma Cohort Study; ASIG: Australian Scleroderma Interest Group; DLCO: Diffusing capacity of the lung for carbon monoxide corrected for haemoglobin; dCSc: Diffuse cutaneous systemic sclerosis; HRCT: High-resolution computed tomography; I.D.: Intestinal lupus disease; lCSc: Limited cutaneous systemic sclerosis; MCTD: Mixed connective tissue disease; NT-pro-BNP: N-terminal pro-B type natriuretic peptide; PAH: Pulmonary arterial hypertension; PH: Pulmonary hypertension; RFTs: Respiratory function tests; RHC: Right-heart catheterisation; SSC: Systemic sclerosis (also known as systemic scleroderma); sPAP: Systolic pulmonary arterial pressure; TR: Tricuspid regurgitation; TTE: Trans-thoracic echocardiogram; WHO: World Health Organisation

Acknowledgements

We would like to acknowledge all investigators of the Australian Scleroderma Interest Group (ASIG) including Catherine Hill, Adelaide, South Australia; Sue Lester, Adelaide, South Australia; Peter Nash, Sunshine Coast, Queensland; Gian Ngiatn, Melbourne Victoria; Mandana Nikpour, Melbourne, Victoria; Susanna Proudman, Adelaide, South Australia; Maureen Rischmueller, Adelaide, South Australia; Janet Roddy, Perth, Western Australia; Joanne Sahar, Melbourne, Victoria; Wendy Stevens, Melbourne, Victoria; Gemma Strickland, Geelong, Victoria; Vivek Thakkar, New South Wales; Jenny Walker, Adelaide, South Australia; Jane Zochling, Hobart, Tasmania.

Funding

This work was supported by Scleroderma Australia, Arthritis Australia, Actelion Australia, Bayer, CSL Biotherapies, GlaxoSmithKline Australia and Pfizer. Dr Morrisroe holds an NHMRC Scholarship (APP1113954). Dr Nikpour holds an NHMRC Fellowship (APP1071735).

Availability of data and materials

All data generated or analysed during this study are included in this published article and its supplementary information files.
12. Galie N, Rubin L, Hoeper M, Jansa P, Ayh-Hit H, Meyer G, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet. 2006;37(1):2093–100.

13. Humbert M, Yaici A, de Groot P, Montani D, Sitbon O, Launay D, et al. Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term survival. Arthritis Rheum. 2011;63:11:3522–30.

14. Chung L, Domsic RT, Lingala B, Alkassab F, Bolster M, Csuka ME, et al. Survival and predictors of mortality in systemic sclerosis-associated pulmonary arterial hypertension: outcomes from the pulmonary hypertension assessment and recognition of outcomes in scleroderma registry. Arthritis Care Res (Hoboken). 2014;66(3):489–95.

15. Barst R, Gibbs JS, Ghofrani HA, Hoeper MM, McLaughlin WV, Rubin LJ, et al. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54(1):Suppl:S78–84.

16. Galie N, Barbera JA, Frost AE, Ghofrani HA, Hoeper MM, McLaughlin WV, et al. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med. 2015;373(9):834–44.

17. Condliffe R, Kiely DG, Peacock AJ, Corris PA, Gibbs JS, Vrapi F, et al. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med. 2009;179(2):151–7.

18. Launay D, Sitbon O, Hachulla E, Mouton D, Ghofrani V, Rottat L, et al. Survival in systemic sclerosis-associated pulmonary arterial hypertension in the modern management era. Ann Rheum Dis. 2013;72(12):1940–6.

19. Morrisey K, HM, Stevens W, Rabbas C, Proudan S, Nilpour M, et al. The Australian Scleroderma Interest Group (ASIG). Risk factors for development of pulmonary arterial hypertension in Australian systemic sclerosis patients: results from a large multicenter cohort study. BMC. 2016.

20. Shah AA, Wigley FM, Hummers LK. Telangiectases in scleroderma: a potential clinical marker of pulmonary arterial hypertension. J Rheumatol. 2010;37(1):98–104.

21. Proudnard S, Stevens W, Sahar J, Celemajer D. Pulmonary arterial hypertension in systemic sclerosis: the need for early detection and treatment. Intern Med. 2007;37(7):485–94.

22. McLaughlin WV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol. 2009;53(17):1573–619.

23. Pauling JD, McHugh NJ. Evaluating factors influencing screening for pulmonary hypertension in systemic sclerosis: does disparity between available guidelines influence clinical practice? Curr Rheumatol. 2012;33(2):357–61.

24. Mangat P, Conron M, Gabbay E, Proudman SM. Scleroderma lung disease: variation in screening, diagnosis and treatment practices between rheumatologists and respiratory physicians. Intern Med J. 2010;40(7):494–502.

25. van den Hoogen F, Hachulla E, Kalden JR, Jewell DM, Edmonds M, Dillehay LM, et al. 2012 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum. 2013;65(11):2737–47.

26. LeRoy EC, Medsger Jr TA. Criteria for the classification of early systemic sclerosis. J Rheumatol. 2001;28(7):1573–6.

27. Sharp GC, Irwin WS, Tan EM, et al. Mixed connective tissue disease: an apparently distinct rheumatic disease syndrome, associated with a specific antibody to extractable nuclear antigen (ENA). Arq J Med. 1972;52(2):148–59.

28. Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery J-L, Barbera JA, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2009;34(6):1219–63.

29. Chaisson NF, Hassoun PM, Chaisson NF, Hassoun PM. Systemic sclerosis-associated pulmonary arterial hypertension. Chest. 2013;144(4):1346–1356.

30. Simonneau G, Gatzoulis MA, Adatia I, Celemajer D, Denton C, Ghofrani A, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2013;62(25 Suppl D):394–411.

31. Englert H, Small-McMahon J, Davis K, O’Connor H, Chambers P, Brooks P. Scleroderma pulmonary hypertension and mortality in Sydney 1974–88. Aust NZ J Med. 1999;29(1):142–50.
Author/s: Morrisroe, K; Stevens, W; Sahhar, J; Rabusa, C; Nikpour, M; Proudman, S

Title: Epidemiology and disease characteristics of systemic sclerosis-related pulmonary arterial hypertension: results from a real-life screening programme

Date: 2017-03-07

Citation: Morrisroe, K., Stevens, W., Sahhar, J., Rabusa, C., Nikpour, M. & Proudman, S. (2017). Epidemiology and disease characteristics of systemic sclerosis-related pulmonary arterial hypertension: results from a real-life screening programme. ARTHRITIS RESEARCH & THERAPY, 19 (1), https://doi.org/10.1186/s13075-017-1250-z.

Persistent Link: http://hdl.handle.net/11343/221583

File Description: Published version

License: CC BY